Thus far, MGMT expression, rather than promoter methylation, appears to better correlate with TMZ response in pituitary adenomas; however, a limited number of studies have examined this relationship, and TMZ is still administered, particularly in the context of aggressive pituitary tumors, regardless of MGMT status (24, 93). The gene discussed is MGMT; the disease is pituitary gland adenoma.